Update on the Prevention and Treatment of Sexually Transmitted Diseases



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

The Centers for Disease Control and Prevention (CDC) recently published updated guidelines that provide new strategies for the prevention and treatment of sexually transmitted diseases (STDs). Patient education is the first important step in reducing the number of persons who engage in risky sexual behaviors. Information on STD prevention should be individualized on the basis of the patient's stage of development and understanding of sexual issues. Other preventive strategies include administering the hepatitis B vaccine series to unimmunized patients who present for STD evaluation and administering hepatitis A vaccine to illegal drug users and men who have sex with men. The CDC recommends against using any form of nonoxynol 9 for STD prevention. New treatment strategies include avoiding the use of quinolone therapy in patients who contract gonorrhea in California or Hawaii. Testing for cure is not necessary if chlamydial infection is treated with a first-line antibiotic (azithromycin or doxycycline). However, all women should be retested three to four months after treatment for chlamydial infection, because of the high incidence of reinfection. Testing for herpes simplex virus serotype is advised in patients with genital infection, because recurrent infection is less likely with the type 1 serotype than with the type 2 serotype. The CDC guidelines also include new information on the treatment of diseases characterized by vaginal discharge.

Despite various attempts by health care workers to reduce the morbidity and mortality of sexually transmitted diseases (STDs), more than 15 million persons acquire STDs each year in the United States.1 Family physicians play a critical role in efforts to prevent or, when prevention fails, to treat these infections. To assist in these endeavors, the Centers for Disease Control and Prevention (CDC)2 recently updated guidelines for the prevention and treatment of STDs.

Clinical Prevention Guidelines

The first portion of the 2002 CDC guidelines discusses the prevention and control of STDs using five major strategies (Table 1).2 The CDC2 notes that the first step in primary prevention is to change sexual behaviors that increase the risk of contracting STDs.

Family physicians are in an excellent position to provide education and counseling on the prevention of STDs. Information should be individualized on the basis of the patient's stage of development and understanding of sexual issues.3 The information should be delivered with respect and compassion, and in a nonjudgmental manner.2 In addition to counseling patients who are being assessed for an STD, family physicians should address possible misconceptions about STD-protective behavior in adolescents and young adults. This type of counseling has been shown to reduce misconceptions, and it also may reduce the occurrence of risky sexual behaviors.4

A nonintensive systematic intervention performed in an outpatient setting (i.e., counseling during the physical examination or visit for refill of a contraceptive prescription) can be effective.5 Over the past 10 years, the use of condoms has increased among at-risk heterosexuals in the United States: this increase suggests that the message on STD prevention is being heard.6 However, to reduce the incidence of STDs, family physicians must continue providing education and counseling.

One of the most reliable methods of avoiding STD transmission is abstinence from sexual relations, including oral, vaginal, and anal sex.2 Education on abstinence can reduce risky sexual behaviors,7 particularly when information on sexual negotiation skills is included.8 Counseling about abstinence is crucial for patients who are receiving treatment for STDs or whose partners are undergoing treatment for STDs, and those who wish to avoid possible consequences of sexual intercourse, such as pregnancy or exposure to an STD.2

The other method for reducing the risk of STD exposure is to be in a long-term monogamous relationship with an uninfected partner. The CDC2 recommends that potential sexual partners be tested for STDs, including human immunodeficiency virus (HIV) infection, before they begin having sexual intercourse. If one of the partners is infected or the infection status is unknown, a new condom should be used for each action of insertive sexual intercourse.

TABLE 1

Major Strategies for the Prevention and Control of STDs

Education and counseling about safer sexual behaviors in persons at risk for STDs

Identification of asymptomatic persons with STDs, as well as symptomatic infected persons who are unlikely to seek diagnostic and treatment services

Effective diagnosis and treatment of persons with STDs

Evaluation, treatment, and counseling of sexual partners of persons with STDs

Preexposure immunizations for vaccine-preventable STDs in selected populations


STDs = sexually transmitted diseases.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

TABLE 1   Major Strategies for the Prevention and Control of STDs

View Table

TABLE 1

Major Strategies for the Prevention and Control of STDs

Education and counseling about safer sexual behaviors in persons at risk for STDs

Identification of asymptomatic persons with STDs, as well as symptomatic infected persons who are unlikely to seek diagnostic and treatment services

Effective diagnosis and treatment of persons with STDs

Evaluation, treatment, and counseling of sexual partners of persons with STDs

Preexposure immunizations for vaccine-preventable STDs in selected populations


STDs = sexually transmitted diseases.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

Preexposure vaccination is one of the most effective strategies for preventing the transmission of certain STDs. The CDC2 recommends that patients being evaluated for an STD receive a hepatitis B vaccine series if they were not immunized in the past. Vaccination is particularly important in adolescents, who generally do not consider themselves to be at risk for contracting hepatitis B.9 The CDC also recommends the administration of hepatitis A vaccine to illegal drug users and men who have sex with men.

Another preventive strategy is the screening of selected populations. The CDC currently recommends annual screening for chlamydial infection in all sexually active women 24 years of age and younger.2 [Evidence level C, consensus/expert guidelines] Screening is important even if these women are asymptomatic, because younger women are more susceptible to chlamydial infection than older women. Women older than 24 years should be screened if they are at risk for chlamydial infection (e.g., new sexual partner, history of multiple sexual partners).2

Nonoxynol 9 is a chemical compound that has been promoted as a potential aid in reducing the transmission of STDs. However, recent studies10,11 have found that this compound provides no protection against gonorrhea or chlamydial infection. In one study,12 the use of nonoxynol 9 actually increased the risk of contracting gonorrhea. Condoms lubricated with nonoxynol 9 have a short shelf life and cost more than other condoms; furthermore, their use may increase the risk of urinary tract infection.2 Because of these factors, the CDC2 recommends against using nonoxynol 9 or condoms lubricated with this compound for preventing the transmission of STDs.

Diseases Characterized by Urethritis and Cervicitis

The diagnosis and treatment of urethritis and cervicitis are discussed in detail in the CDC guidelines.2 New information includes the wider spread of quinolone resistance to Neisseria gonorrhoeae and the need for follow-up testing in women treated for chlamydial infection.

GONOCOCCAL DISEASE

Since the last CDC recommendations were published, resistance to quinolones has spread to Hawaii and parts of the West Coast. Based on epidemiology, resistance to these drugs is believed to have originated in Asia and the Pacific region; the incidence of quinolone resistance has been high in these areas for some time. In Hawaii, quinolones are no longer recommended for the treatment of gonorrhea. The CDC2 suggests that, because of the increased prevalence of resistant N. gonorrhoeae, quinolone therapy is “inadvisable” in California as well.

Cephalosporins, specifically orally administered cefixime (Suprax) and intramuscularly administered ceftriaxone (Rocephin), are first-line agents for the treatment of gonococcal urethritis (Table 2).2 Ceftriaxone, which remains the agent of choice for other forms of gonococcal disease, is given intravenously to treat all serious or systemic infections.

TABLE 2

Treatment Recommendations for STDs Characterized by Urethritis and Cervicitis

Disease Preferred treatment Alternative treatment

Uncomplicated gonorrhea

Cefixime (Suprax), 400 mg orally one time Ceftriaxone (Rocephin), 125 mg IM one time* Ciprofloxacin (Cipro), 500 mg orally one time Ofloxacin (Floxin), 400 mg orally one time Levofloxacin (Levaquin), 250 mg orally one time

Spectinomycin (Trobicin), 2 g IM one time

Ceftizoxime (Cefizox), 500 mg IM one time

Cefoxitin (Mefoxin), 2 g IM one time, plus probenecid, 1 g orally one time

Cefotaxime (Claforan), 500 mg IM one time

Gatifloxacin (Tequin), 400 mg orally one time

Norfloxacin (Noroxin), 800 mg orally one time

Lomefloxacin (Maxaquin), 400 mg orally one time

Chlamydial infection

Azithromycin (Zithromax), 1 g orally one time Doxycycline (Vibramycin), 100 mg orally twice daily for 7 days

Erythromycin base, 500 mg orally four times daily for 7 days

Erythromycin ethylsuccinate (E.E.S.), 800 mg orally four times daily for 7 days

Ofloxacin, 300 mg orally twice daily for 7 days

Levofloxacin, 500 mg orally once daily for 7 days

Persistent urethritis

Metronidazole (Flagyl), 2 g orally one time, plus erythromycin base, 500 mg orally four times daily for 7 days, or erythromycin ethylsuccinate, 800 mg orally four times daily for 7 days


STDs = sexually transmitted diseases; IM = intramuscularly.

*—No advantage exists for use of the alternative injectable cephalosporins over ceftriaxone; in addition, no advantage exists for use of orally administered quinolones over the first-line quinolones, and data on their use are limited.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

TABLE 2   Treatment Recommendations for STDs Characterized by Urethritis and Cervicitis

View Table

TABLE 2

Treatment Recommendations for STDs Characterized by Urethritis and Cervicitis

Disease Preferred treatment Alternative treatment

Uncomplicated gonorrhea

Cefixime (Suprax), 400 mg orally one time Ceftriaxone (Rocephin), 125 mg IM one time* Ciprofloxacin (Cipro), 500 mg orally one time Ofloxacin (Floxin), 400 mg orally one time Levofloxacin (Levaquin), 250 mg orally one time

Spectinomycin (Trobicin), 2 g IM one time

Ceftizoxime (Cefizox), 500 mg IM one time

Cefoxitin (Mefoxin), 2 g IM one time, plus probenecid, 1 g orally one time

Cefotaxime (Claforan), 500 mg IM one time

Gatifloxacin (Tequin), 400 mg orally one time

Norfloxacin (Noroxin), 800 mg orally one time

Lomefloxacin (Maxaquin), 400 mg orally one time

Chlamydial infection

Azithromycin (Zithromax), 1 g orally one time Doxycycline (Vibramycin), 100 mg orally twice daily for 7 days

Erythromycin base, 500 mg orally four times daily for 7 days

Erythromycin ethylsuccinate (E.E.S.), 800 mg orally four times daily for 7 days

Ofloxacin, 300 mg orally twice daily for 7 days

Levofloxacin, 500 mg orally once daily for 7 days

Persistent urethritis

Metronidazole (Flagyl), 2 g orally one time, plus erythromycin base, 500 mg orally four times daily for 7 days, or erythromycin ethylsuccinate, 800 mg orally four times daily for 7 days


STDs = sexually transmitted diseases; IM = intramuscularly.

*—No advantage exists for use of the alternative injectable cephalosporins over ceftriaxone; in addition, no advantage exists for use of orally administered quinolones over the first-line quinolones, and data on their use are limited.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

Quinolones are safe and effective for treating nonresistant gonococcal infections. However, these drugs should be used with caution when an infection may have been acquired in or from Asia or the Pacific region. Ciprofloxacin (Cipro) and ofloxacin (Floxin) are options for the intravenous treatment of disseminated gonococcal infections and are given orally for the treatment of uncomplicated infections of the urethra, cervix, or rectum.2

NONGONOCOCCAL URETHRITIS

Etiologic agents in nongonococcal urethritis include Chlamydia trachomatis, Mycoplasma genitalium, and Ureaplasma urealyticum. Rarely, nongonococcal urethritis is caused by Trichomonas vaginalis or herpes simplex virus (HSV).

The recommended treatment for non-gonococcal urethritis (e.g., chlamydial infection) is azithromycin (Zithromax) or doxycycline (Vibramycin). Alternatively, the infection can be treated with a seven-day course of erythromycin base or erythromycin ethylsuccinate (E.E.S), ofloxacin, or levofloxacin (Levaquin).2 The CDC encourages testing for C. trachomatis in all patients with urethritis and cervicitis, and recommends treatment of gonorrhea and chlamydial infection if empiric therapy is initiated before test results are known or when patients are likely to be lost to follow-up.2 [Evidence level C, consensus/expert guidelines]

PERSISTENT URETHRITIS

Rarely, symptoms persist after routine therapy. Unfortunately, there is no proven effective treatment for persistent urethritis. Recommendations include repeating the initial therapy if the patient did not comply with the original treatment plan. If the patient was compliant, consideration can be given to swab testing for T. vaginalis and treatment with metronidazole (Flagyl) and erythromycin.

CHLAMYDIAL INFECTION

The updated CDC guidelines2 include follow-up strategies for use in women with chlamydial infection. Unless symptoms persist, testing for cure is unnecessary when a chlamydial infection is treated with azithromycin or doxycycline. If retesting is indicated, it should be delayed for more than three weeks after treatment is completed to reduce the possibility of a false-positive result.

The CDC2 notes that patients who have had a chlamydial infection are at high risk for reinfection. Therefore, all women with previous chlamydial infection should be retested three to four months after treatment. Regardless of whether their sexual partner has been treated, these women should be rescreened by no later than 12 months after the infection.2

Diseases Characterized by Genital Ulcers

In the United States, the most common causes of genital ulcers are genital herpes, syphilis, and chancroid.2,13 Each of these diseases is associated with an increased risk for HIV infection.2 The only significant change in the CDC recommendations concerns HSV infection.

GENITAL HERPES

HSV infection is the most common cause of genital ulcers in this country.13 Approximately 45 to 50 million Americans have genital herpes, and an estimated 1 million new cases occur each year.2,14 Primary infection occurs mostly in adolescents and young adults. Genital herpes is more common in women, blacks, and persons with multiple sexual partners.

Two HSV serotypes have been identified in humans. HSV-1 is the most common cause of oral herpes infection, and HSV-2 is the primary pathogen in sexually transmitted genital herpes. Both serotypes can be present at oral or genital sites.

HSV infection can be characterized by episodes of latency, with asymptomatic viral shedding, recurrent activation, and perinatal and sexual transmission.15 Along with most common genital ulcerative diseases, HSV infection increases the risk of HIV transmission and is believed to play an important role in the heterosexual spread of HIV.16

The diagnosis of genital herpes is best established by viral culture. In the updated guidelines, the CDC2 also recommends type-specific serologic testing to determine which HSV serotype has caused the genital infection. Knowing the HSV serotype is important in counseling patients about the potential for recurrent genital herpes, because recurrent episodes are less likely with the HSV-1 serotype than with the HSV-2 serotype. In addition, type-specific serologic tests may help confirm the diagnosis of genital herpes in patients with recurrent infection or with healing lesions, for which HSV culture results may be false-negative.

The treatment of genital herpes depends on whether the infection is a first episode or a recurrence (Table 3).2 The CDC2 also has established regimens for suppressive therapy in patients with recurrent genital herpes.

Diseases Characterized by Vaginal Discharge

Bacterial vaginosis, trichomoniasis, and candidiasis are the most common diseases associated with vaginal discharge. Patients with any of these diseases also may have vulvar itching or irritation and a vaginal odor.

TABLE 3

Treatment Regimens for Genital Herpes

First episode*

Acyclovir (Zovirax), 400 mg orally three times daily for 7 to 10 days, or 200 mg orally five times daily for 7 to 10 days

Famciclovir (Famvir), 250 mg orally three times daily for 7 to 10 days

Valacyclovir (Valtrex), 1 g orally twice daily for 7 to 10 days

Recurrent episode

Acyclovir, 400 mg orally three times daily for 5 days, or 200 mg orally five times daily for 5 days, or 800 mg orally twice daily for 5 days

Famciclovir, 125 mg orally twice daily for 5 days

Valacyclovir, 500 mg orally twice daily for 3 to 5 days, or 1 g orally once daily for 5 days

Suppressive therapy

Acyclovir, 400 mg orally twice daily

Famciclovir, 250 mg orally twice daily

Valacyclovir, 500 mg orally once daily, or 1 g orally once daily


*—Antiviral drug therapy may be extended if healing is incomplete after 10 days.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

TABLE 3   Treatment Regimens for Genital Herpes

View Table

TABLE 3

Treatment Regimens for Genital Herpes

First episode*

Acyclovir (Zovirax), 400 mg orally three times daily for 7 to 10 days, or 200 mg orally five times daily for 7 to 10 days

Famciclovir (Famvir), 250 mg orally three times daily for 7 to 10 days

Valacyclovir (Valtrex), 1 g orally twice daily for 7 to 10 days

Recurrent episode

Acyclovir, 400 mg orally three times daily for 5 days, or 200 mg orally five times daily for 5 days, or 800 mg orally twice daily for 5 days

Famciclovir, 125 mg orally twice daily for 5 days

Valacyclovir, 500 mg orally twice daily for 3 to 5 days, or 1 g orally once daily for 5 days

Suppressive therapy

Acyclovir, 400 mg orally twice daily

Famciclovir, 250 mg orally twice daily

Valacyclovir, 500 mg orally once daily, or 1 g orally once daily


*—Antiviral drug therapy may be extended if healing is incomplete after 10 days.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

BACTERIAL VAGINOSIS

Bacterial vaginosis is caused by the replacement of normal vaginal flora with an overgrowth of anaerobic microorganisms, Mycoplasma hominis, and Gardnerella vaginalis. This disease is the most frequent cause of vaginal discharge, but most affected women are asymptomatic.

The current controversy about bacterial vaginosis concerns screening for and treating this disease in pregnant women. The presence of bacterial vaginosis during pregnancy has been associated with premature rupture of membranes, preterm labor, preterm birth, chorioamnionitis, postpartum endometritis, and postcesarean section infection. However, routine screening for and treatment of bacterial vaginosis during the prenatal period have not been shown to reduce these adverse pregnancy outcomes.1720 [References17 and18—Evidence level A, randomized controlled trials (RCTs); reference19—Evidence level A, meta-analysis; reference20—Evidence level A, systematic review of RCTs]

The CDC2 recommends screening for bacterial vaginosis in all symptomatic pregnant women, followed by treatment if indicated. Testing for bacterial vaginosis also may be performed in pregnant women who have a history of preterm labor, with treatment given if disease is present. However, the optimal treatment regimen for these patients has not been established.

TRICHOMONIASIS

Men with trichomoniasis tend to be asymptomatic, but infected women tend to have a diffuse, malodorous, yellow-green vaginal discharge that causes vulvar irritation. Trichomoniasis is diagnosed by the presence of moving flagellated organisms in vaginal secretions viewed under a microscope.

Topical agents administered vaginally do not provide adequate coverage for trichomoniasis. The recommended treatment for this infection is metronidazole, taken orally in a single 2-g dose. Alternatively, metronidazole can be administered in a dosage of 500 mg orally twice daily for seven days.2

Pregnant women with symptomatic trichomoniasis should be given a single dose of metronidazole.21 Treatment of asymptomatic trichomoniasis during pregnancy has not been shown to prevent preterm delivery.22 [Evidence level A, RCT]

TABLE 4

Diagnostic Criteria for PID

Minimum criteria

Uterine or adnexal tenderness

or

Cervical motion tenderness

Additional criteria

Oral temperature >38.3°C (>101°F)

Abnormal cervical or vaginal mucopurulent discharge

Presence of white blood cells on saline microscopy of vaginal secretions

Laboratory documentation of cervical gonococcal or chlamydial infection

Elevated C-reactive protein level

Elevated erythrocyte sedimentation rate

Specific criteria

Endometrial biopsy with histopathologic evidence of endometritis

Laparoscopic abnormalities consistent with PID

Transvaginal ultrasound or MRI study showing thickened, fluid-filled tubes, with or without free pelvic fluid or tubo-ovarian complex


PID = pelvic inflammatory disease; MRI = magnetic resonance imaging.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

TABLE 4   Diagnostic Criteria for PID

View Table

TABLE 4

Diagnostic Criteria for PID

Minimum criteria

Uterine or adnexal tenderness

or

Cervical motion tenderness

Additional criteria

Oral temperature >38.3°C (>101°F)

Abnormal cervical or vaginal mucopurulent discharge

Presence of white blood cells on saline microscopy of vaginal secretions

Laboratory documentation of cervical gonococcal or chlamydial infection

Elevated C-reactive protein level

Elevated erythrocyte sedimentation rate

Specific criteria

Endometrial biopsy with histopathologic evidence of endometritis

Laparoscopic abnormalities consistent with PID

Transvaginal ultrasound or MRI study showing thickened, fluid-filled tubes, with or without free pelvic fluid or tubo-ovarian complex


PID = pelvic inflammatory disease; MRI = magnetic resonance imaging.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

VULVOVAGINAL CANDIDIASIS

Vulvovaginal candidiasis usually presents as pruritus and vulvovaginal erythema. The diagnosis of this infection can be confirmed by finding budding yeast or hyphae under a microscope after a 10 percent potassium hydroxide solution has been added to vaginal secretions. Current treatment recommendations include a substantial number of over-the-counter (OTC) antifungal agents, as well as prescription fluconazole (Diflucan) taken orally in a single 150-mg dose.2

An important concern is that women frequently self-diagnose vulvovaginal candidiasis incorrectly.2,23 The CDC2 notes that unnecessary or inappropriate use of OTC antifungal agents can delay correct diagnosis and treatment of vulvovaginitis resulting from other causes. Hence, self-medication with antifungal agents should be done only for recurrence of symptoms in women who have been diagnosed with vulvovaginal candidiasis by a health care professional. Women who use OTC antifungal agents should be advised to seek medical care if their symptoms do not resolve or if their symptoms recur within two months after OTC antifungal treatment.

TABLE 5

Treatment Regimens for PID

Parenteral regimen A

Cefotetan (Cefotan), 2 g IV every 12 hours, or cefoxitin (Mefoxin), 2 g IV every 6 hours

plus

Doxycycline (Vibramycin), 100 mg orally or IV every 12 hours

Parenteral regimen B

Clindamycin (Cleocin), 900 mg IV every 8 hours

plus

Gentamicin, 2 mg per kg IV or IM (loading dose), followed by 1.5 mg per kg IM or IV every 8 hours (maintenance dosage; single daily dosing may be substituted)

Alternative parenteral regimens

Ofloxacin (Floxin), 400 mg IV every 12 hours, or levofloxacin (Levaquin), 500 mg IV once daily

with or without

Metronidazole (Flagyl), 500 mg IV every 8 hours, or ampicillinsulbactam (Unasyn), 3 g IV every 6 hours

plus

Doxycycline, 100 mg orally or IV every 12 hours

Outpatient regimen A

Ofloxacin, 400 mg orally twice daily for 14 days, or levofloxacin, 500 mg orally once daily for 14 days

with or without

Metronidazole, 500 mg orally twice daily for 14 days

Outpatient regimen B

Ceftriaxone (Rocephin), 250 mg IM one time; or cefoxitin, 2 g IM, plus probenecid, I g orally administered concurrently; or other parenterally administered third-generation cephalosporin (e.g., ceftizoxime [Cefizox], cefotaxime [Claforan])

plus

Doxycycline, 100 mg orally twice daily for 14 days

with or without

Metronidazole, 500 mg orally twice daily for 14 days


PID = pelvic inflammatory disease; IV = intravenously; IM = intramuscularly.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

TABLE 5   Treatment Regimens for PID

View Table

TABLE 5

Treatment Regimens for PID

Parenteral regimen A

Cefotetan (Cefotan), 2 g IV every 12 hours, or cefoxitin (Mefoxin), 2 g IV every 6 hours

plus

Doxycycline (Vibramycin), 100 mg orally or IV every 12 hours

Parenteral regimen B

Clindamycin (Cleocin), 900 mg IV every 8 hours

plus

Gentamicin, 2 mg per kg IV or IM (loading dose), followed by 1.5 mg per kg IM or IV every 8 hours (maintenance dosage; single daily dosing may be substituted)

Alternative parenteral regimens

Ofloxacin (Floxin), 400 mg IV every 12 hours, or levofloxacin (Levaquin), 500 mg IV once daily

with or without

Metronidazole (Flagyl), 500 mg IV every 8 hours, or ampicillinsulbactam (Unasyn), 3 g IV every 6 hours

plus

Doxycycline, 100 mg orally or IV every 12 hours

Outpatient regimen A

Ofloxacin, 400 mg orally twice daily for 14 days, or levofloxacin, 500 mg orally once daily for 14 days

with or without

Metronidazole, 500 mg orally twice daily for 14 days

Outpatient regimen B

Ceftriaxone (Rocephin), 250 mg IM one time; or cefoxitin, 2 g IM, plus probenecid, I g orally administered concurrently; or other parenterally administered third-generation cephalosporin (e.g., ceftizoxime [Cefizox], cefotaxime [Claforan])

plus

Doxycycline, 100 mg orally twice daily for 14 days

with or without

Metronidazole, 500 mg orally twice daily for 14 days


PID = pelvic inflammatory disease; IV = intravenously; IM = intramuscularly.

Adapted from Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51(RR-6):1–78.

PELVIC INFLAMMATORY DISEASE

Pelvic inflammatory disease (PID) encompasses a range of inflammatory disorders that affect the female upper genital tract. The most common causes are C. trachomatis and N. gonorrhoeae. Other possible causes include anaerobes, G. vaginalis, Haemophilus influenzae, enteric gram-negative rods, Streptococcus agalactiae, cytomegalovirus, M. hominis, and U. urealyticum.

The CDC has developed diagnostic criteria for PID (Table 4).2 The updated CDC guidelines2 state that to reduce morbidity from PID, empiric therapy should be initiated in patients who have uterine or adnexal tenderness or cervical motion tenderness (minimum diagnostic criteria), with treatment based on the individual patient's risk profile. In one recent study,24 adnexal tenderness was found to be the most sensitive diagnostic criterion. Additional criteria can be used to support the diagnosis of PID.2

The CDC updated treatment regimens for PID to include levofloxacin in the alternative parenteral regimen and one of the outpatient regimens (Table 5).2

The Authors

KARL E. MILLER, M.D., is professor in the Department of Family Medicine at the University of Tennessee College of Medicine, Chattanooga. After graduating from the Medical College of Ohio, Toledo, Dr. Miller completed a family practice residency at Flower Memorial Hospital, Sylvania, Ohio. He also completed a research and faculty development fellowship at Michigan State University, East Lansing. Dr. Miller is assistant editor of American Family Physician.

DAVID E. RUIZ, M.D., is assistant professor in the Department of Family Medicine at the University of Tennessee College of Medicine, Chattanooga. A graduate of Loma Linda (Calif.) University School of Medicine, Dr. Ruiz completed a family practice residency at Florida Hospital, Orlando, and a faculty development fellowship at the University of North Carolina at Chapel Hill.

J. CHRISTOPHER GRAVES, M.D., is assistant professor in the Department of Family Medicine at the University of Tennessee College of Medicine, Chattanooga. Dr. Graves received his medical degree from the University of Tennessee Center for Health Sciences, Memphis, and completed family practice residencies at Saint Francis Hospital, Memphis, and Naval Hospital, Camp Pendleton, Calif.

Address correspondence to Karl E. Miller, M.D., Department of Family Medicine, Chattanooga Unit, University of Tennessee College of Medicine, 1100 E. Third St., Chattanooga, TN 37403 (e-mail: millerkarle@hotmail.com). Reprints are not available from the authors.

The authors indicate that they do not have any conflicts of interest. Sources of funding: none reported.

REFERENCES

1. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis. 1999;264 suppl:S2–7.

2. Sexually transmitted diseases treatment guidelines 2002. . Centers for Disease Control and Prevention. MMWR Recomm Rep. 2002;51RR-6:1–78.

3. Shrier LA, Ancheta R, Goodman E, Chiou VM, Lyden MR, Emans SJ. Randomized controlled trial of a safer sex intervention for high-risk adolescent girls. Arch Pediatr Adolesc Med. 2001;155:73–9.

4. Crosby RA, Newman D, Kamb ML, Zenilman J, Douglas JM Jr, Iatesta M. Misconceptions about STD-protective behavior. Project RESPECT Study Group. Am J Prev Med. 2000;19:167–73.

5. Dodge WT, BlueSpruce J, Grothaus L, Rebolledo V, McAfee TA, Carey JW, et al. Enhancing primary care HIV prevention: a comprehensive clinical intervention. Am J Prev Med. 2001;20:177–83.

6. Catania JA, Canchola J, Binson D, Dolcini MM, Paul JP, Fisher L, et al. National trends in condom use among at-risk heterosexuals in the United States. J Acquir Immune Defic Syndr. 2001;27:176–82.

7. Aten MJ, Siegel DM, Enaharo M, Auinger P. Keeping middle school students abstinent: outcomes of a primary prevention intervention. J Adolesc Health. 2002;31:70–8.

8. Shepherd J, Weston R, Peersman G, Napuli IZ. Interventions for encouraging sexual lifestyles and behaviours intended to prevent cervical cancer. Cochrane Database Syst Rev. 2000;(2):CD001035.

9. Schmidt RM, Middleman AB. The importance of hepatitis B vaccination among adolescents. J Adolesc Health. 2001;29:217–22.

10. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Tweedy KG. Effect of nonoxynol-9 gel on urogenital gonorrhea and chlamydial infection: a randomized controlled trial. JAMA. 2002;287:1117–22.

11. Roddy RE, Zekeng L, Ryan KA, Tamoufe U, Weir SS, Wong EL. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med. 1998;339:504–10.

12. Richardson BA, Lavreys L, Martin HL Jr, Stevens CE, Ngugi E, Mandaliya K, et al. Evaluation of a low-dose nonoxynol-9 gel for the prevention of sexually transmitted diseases: a randomized clinical trial. Sex Transm Dis. 2001;28:394–400.

13. Gevelber MA, Biro FM. Adolescents and sexually transmitted diseases. Pediatr Clin North Am. 1999;46:747–66.

14. Miller KE, Graves JC. Update on the prevention and treatment of sexually transmitted diseases. Am Fam Physician. 2000;61:379–86.

15. Woodward C, Fisher MA. Drug treatment of common STDs: part I. Herpes, syphilis, urethritis, chlamydia and gonorrhea. Am Fam Physician. 1999;60:1387–94.

16. Czelusta A, Yen-Moore A, Van der Straten M, Carrasco D, Tyring SK. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 2000;43:409–32.

17. Carey JC, Klebanoff MA, Hauth JC, Hillier SL, Thom EA, Ernest JM, et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med. 2000;342:534–40.

18. Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol. 2001;975 pt 1:643–8.

19. Guise JM, Mahon SM, Aickin M, Helfand M, Peipert JF, Westhoff C. Screening for bacterial vaginosis in pregnancy. Am J Prev Med. 2001;203 suppl:62–72.

20. Brocklehurst P, Hannah M, McDonald H. Interventions for treating bacterial vaginosis in pregnancy. Cochrane Database Syst Rev. 2000;(2):CD000262.

21. Gulmezoglu AM. Interventions for trichomoniasis in pregnancy. Cochrane Database Syst Rev. 2002;(3):CD000220.

22. Klebanoff MA, Carey JC, Hauth JC, Hillier SL, Nugent RP, Thom EA, et al. Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomaticTrichomonas vaginalis infection. N Engl J Med. 2001;345:487–93.

23. Sihvo S, Ahonen R, Mikander H, Hemminki E. Self-medication with vaginal antifungal drugs: physicians' experiences and women's utilization patterns. Fam Pract. 2000;172:145–9.

24. Peipert JF, Ness RB, Blume J, Soper DE, Holley R, Randall H, et al. Clinical predictors of endometritis in women with symptoms and signs of pelvic inflammatory disease. Am J Obstet Gynecol. 2001;184:856–63.


Copyright © 2003 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Download PDF
  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in Pubmed

Navigate this Article